Skip to content

Study · In vitro (cell-free) · 2026

8 results

LL-37-ApoB-100 Complex Serves as a Biomarker of Coronary Artery Disease.

Fang Y, Zhang Z, Cao Q, Li Y, Duan Y, Meng P, Duan Z, Wang G, Gao J, Hua M, Huang B, Zhou T and 11 more

Show all authors

Zhang H, Kong F, Zhang Y, Li M, Ma ZS, Li Y, Wang Z, Cheng R, Lu Q, Ni H, Lai R

Arteriosclerosis, thrombosis, and vascular biology9 Apr 2026Cited by 1 (Europe PMC)

PMID41953980 (opens in a new tab)DOI10.1161/atvbaha.125.323486 (opens in a new tab)PepBankPUB-41953980
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cell-free)Mechanism

    In cell-free binding assays, LL‑37 interacted directly with multiple distinct binding sites on ApoB-100.

    In plain wordsIn lab tests, LL‑37 bound directly to several sites on the ApoB-100 protein.

    Peptide
    LL-37
    Outcome
    Not applicableLL-37 binding to ApoB-100
    Study

    n: not reported in source

    Surface plasmon resonance and protein-protein docking
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We identified that LL-37 directly interacted with multiple distinct binding sites on ApoB-100.
    1 context sentence
    Summary · context
    We performed surface plasmon resonance and protein-protein docking to demonstrate the direct LL-37-ApoB-100 interaction.

Natural levels measured7

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 02HumanEndogenous levelObservational studyOther

    Plasma levels of the body's own LL‑37-ApoB-100 complex were higher in patients with atherosclerosis.

    In plain wordsPatients with atherosclerosis had higher levels of the body's own LL‑37-ApoB-100 complex in their blood.

    Peptide
    LL-37
    Outcome
    IncreasePlasma LL-37-ApoB-100 complex in atherosclerosis
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    Plasma levels of LL-37-ApoB-100 complex were significantly elevated in human patients with atherosclerosis.
    1 context sentence
    Summary · context
    An observational case-control study of 1103 patients undergoing coronary angiography from 2 independent centers assessed the association between LL-37-ApoB-100 and obstructive CAD.

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

  2. 03HumanEndogenous levelObservational studyOther

    In the center 1 cohort, plasma LL‑37-ApoB-100 levels were higher in patients with obstructive coronary artery disease.

    In plain wordsPatients with obstructive coronary artery disease had higher levels of the body's own LL‑37-ApoB-100 complex in their blood.

    Peptide
    LL-37
    Outcome
    IncreaseComplex level in obstructive CAD (center 1)
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    In the observational cohort from center 1, plasma LL-37-ApoB-100 levels were also significantly elevated in patients with obstructive CAD
    1 context sentence
    Summary · context
    An observational case-control study of 1103 patients undergoing coronary angiography from 2 independent centers assessed the association between LL-37-ApoB-100 and obstructive CAD.

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

  3. 04HumanEndogenous levelObservational studyOther

    In the center 1 cohort, plasma LL‑37-ApoB-100 levels correlated positively with disease severity by Gensini score.

    In plain wordsHigher levels of the body's own LL‑37-ApoB-100 complex were linked to more severe coronary disease.

    Peptide
    LL-37
    Outcome
    IncreaseComplex level versus Gensini score
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    correlation r
    0.6 r
    Gensini score

    Source sentences

    Summary
    In the observational cohort from center 1, plasma LL-37-ApoB-100 levels were also significantly elevated in patients with obstructive CAD and strongly correlated with disease severity (Gensini score; r=0.60, P<0.001).
    1 context sentence
    Summary · context
    An observational case-control study of 1103 patients undergoing coronary angiography from 2 independent centers assessed the association between LL-37-ApoB-100 and obstructive CAD.

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

  4. 05HumanEndogenous levelObservational studyOther

    LL‑37-ApoB-100 complex level discriminated obstructive coronary artery disease with an area under the curve of 0.82.

    In plain wordsThe body's own LL‑37-ApoB-100 complex level helped tell apart patients with obstructive coronary artery disease.

    Peptide
    LL-37
    Outcome
    Not applicableDiagnostic accuracy for obstructive CAD
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    AUC
    0.82 AUC
    obstructive CAD diagnosis

    Source sentences

    Summary
    Receiver operating characteristic curve analysis further demonstrated that LL-37-ApoB-100 was a valuable biomarker for the diagnosis of obstructive CAD, with an area under the curve of 0.82 (95% CIs, 0.81-0.85, P<0.001).
    1 context sentence
    Summary · context
    An observational case-control study of 1103 patients undergoing coronary angiography from 2 independent centers assessed the association between LL-37-ApoB-100 and obstructive CAD.

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

  5. 06HumanEndogenous levelObservational studyOther

    After adjustment, elevated LL‑37-ApoB-100 levels remained an independent predictor of obstructive CAD in the upper quartiles.

    In plain wordsHigher levels of the body's own LL‑37-ApoB-100 complex were linked to obstructive coronary artery disease, after adjustment.

    Peptide
    LL-37
    Outcome
    IncreaseAdjusted odds of obstructive CAD
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    adjusted odds ratio
    6.51 OR
    upper quartiles

    Source sentences

    Summary
    After adjustment for lipid and clinical measures, elevated LL-37-ApoB-100 levels remained an independent predictor of obstructive CAD, with an adjusted odds ratio of 6.51 (95% CI, 4.34-9.77, P<0.001) for the upper quartiles.
    1 context sentence
    Summary · context
    An observational case-control study of 1103 patients undergoing coronary angiography from 2 independent centers assessed the association between LL-37-ApoB-100 and obstructive CAD.

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

  6. 07HumanEndogenous levelObservational studyOther

    In the center 2 cohort, observational analyses showed results consistent with center 1.

    In plain wordsA second center found results consistent with the first for the body's own LL‑37-ApoB-100 complex.

    Peptide
    LL-37
    Outcome
    IncreaseComplex level in obstructive CAD (center 2)
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    Observational analyses in center 2 showed consistent results.
    1 context sentence
    Summary · context
    An observational case-control study of 1103 patients undergoing coronary angiography from 2 independent centers assessed the association between LL-37-ApoB-100 and obstructive CAD.

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

  7. 08AnimalEndogenous levelAnimal study (in vivo)Other

    In Apoe-/- mice, levels of the LL‑37-ApoB-100 complex correlated positively with atherosclerotic plaque area.

    In plain wordsIn mice prone to atherosclerosis, higher levels of the body's own LL‑37-ApoB-100 complex went with larger plaques.

    Peptide
    LL-37
    Outcome
    IncreaseLL-37-ApoB-100 complex versus plaque area
    Study

    mousen: not reported in source

    Apoe-/- mice
    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    Consistently, levels of this complex were positively correlated with atherosclerotic plaque area in Apoe-/- mice.
    1 context sentence
    Summary · context
    We developed a specific polyclonal antibody against the complex and measured its levels in human atherosclerotic plaques and plasma, as well as in Apoe-/- mice.

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.